WO2003070245A1 - Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists - Google Patents

Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists Download PDF

Info

Publication number
WO2003070245A1
WO2003070245A1 PCT/US2003/004592 US0304592W WO03070245A1 WO 2003070245 A1 WO2003070245 A1 WO 2003070245A1 US 0304592 W US0304592 W US 0304592W WO 03070245 A1 WO03070245 A1 WO 03070245A1
Authority
WO
WIPO (PCT)
Prior art keywords
dopamine
substituted
compound
ester
acetyl
Prior art date
Application number
PCT/US2003/004592
Other languages
French (fr)
Other versions
WO2003070245B1 (en
Inventor
Durk Dijkstra
Hakan Wikstrom
Original Assignee
Darpharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200478A external-priority patent/SE0200478D0/en
Priority claimed from SE0200474A external-priority patent/SE0200474D0/en
Priority to EP03713475A priority Critical patent/EP1480647B1/en
Priority to AU2003217430A priority patent/AU2003217430B2/en
Priority to DK03713475T priority patent/DK1480647T3/en
Priority to US10/503,796 priority patent/US7220754B2/en
Application filed by Darpharma, Inc. filed Critical Darpharma, Inc.
Priority to DE60323339T priority patent/DE60323339D1/en
Priority to CA002476115A priority patent/CA2476115A1/en
Priority to JP2003569201A priority patent/JP2005526728A/en
Publication of WO2003070245A1 publication Critical patent/WO2003070245A1/en
Publication of WO2003070245B1 publication Critical patent/WO2003070245B1/en
Priority to NO20043634A priority patent/NO20043634L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings

Definitions

  • This invention relates to novel mono-ester and asymmetrically substituted di-ester pro-drugs of dopamine Dl receptor agonists, useful for treating dopamine-related neurological, psychological, cardiovascular, cognitive and behavioral disorders.
  • Dopamine is an important neurotransmitter in the central nervous system (CNS), as where it is involved with motor function, perception, arousal, motivation and emotion. Dopamine imbalance is believed to play a key role in a number of CNS-related disorders such as schizophrenia, Parkinson's disease, drug abuse, eating disorders and depression. Dopamine also has several important roles in the peripheral nervous system, such as in the control of blood to the kidneys and in autotonomic ganglion transmission.
  • Dopamine receptors in the CNS have traditionally been divided into two general categories, designated D-l and D-2 receptors, based on biochemical and pharmacological differences between the two receptor types, and more recently from the study of the molecular biology of dopamine receptors in the CNS. (For a review of the classification and function of dopamine receptor subtypes, see C. Kaiser and T.
  • a particular dopamine-related problem involves the loss of striatal dopamine within the basal ganglia, the region of the mammalian brain that is involved with motor control, which has been established as the fundamental deficit in Parkinson's Disease and primary to the etiology of that disease state.
  • This deficiency is addressed via dopamine replacement therapy, primarily with L DOPA (3,4-dihydroxyphenylalanine), which is converted to dopamine within the brain.
  • L-DOPA has been the cornerstone of Parkinson's Disease therapy, and the successes achieved with its therapy have led to the testing of other compounds capable of eliciting the post-synaptic receptor actions of dopamine.
  • Bromocriptine the most widely used direct-acting dopamine agonist for the treatment of Parkinson's Disease, is administered adjunctively with L-DOPA in order to lower dosage of L-DOPA required to achieve the desired therapeutic response.
  • Bromocriptine alone has been shown to relieve Parkinson's Disease symptoms in some patients, allowing for a delay in the onset of L-DOPA therapy, but the response to bromocriptine alone is not as great as that observed with L DOPA.
  • the current therapies for Parkinson's Disease, including L-DOPA and bromocriptine are, however, unfortunately associated with a number of serious side-effects and limitations, such as the development of dyskinesias, severe response fluctuations (on- off phenomenon) and diminishing efficacy during treatment.
  • Anti-schizophrenic drugs are postulated to exert their effects by blocking the dopamine receptors (i.e., acting as receptor antagonists), and consequently preventing excess receptor stimulation (G.P. Reynolds, "Developments in the drug treatment of schizophrenia", in TIPS, :116-121, 1992).
  • These antipsychotic agents frequently produce undesirable side-effects, however, the most common of which are the extrapyramidal effects that include unusual involuntary movements and Parkinson-like states, as well as sedation and hypotension. Because of these often severe side-effects and the high incidence of patients unresponsive to dopamine blocking drugs, novel and improved therapies continue to be sought.
  • dopamine receptor antagonists have included the use of low doses of dopamine agonists, such as apomorphine and bromocriptine. which have been reported to produce anti psychotic effects, possibly due to preferential activation of dopamine presynaptic receptors resulting in decreased dopaminergic activity (M. Del Zompo et al, "Dopamine agonists in the treatment of schizophrenia", Progress in Brain Research, E:41-48, 1986 end H. Y. Meltzer, "Novel Approaches to the Pharmacology of Schizophrenia", Drug Development Research, 9:23-40, 1986).
  • dopamine agonists such as apomorphine and bromocriptine
  • the dopamine Dl-selective agonist, SKF 38393, when used in conjunction with the antipsychotic drug, haloperidol, a D2 antagonist, has been shown to ameliorate the undesired side-effects of the haloperidol (M. Davidson, "Effects of the D-1 Agonist SKF-38393 Combined With Haloperidol in Schizophrenic Patients", Arch Gen. Psychiatry, 42 : 190- 191 , 1990).
  • D-1 agonist SKE 38393
  • SKE 38393 The D-1 agonist, SKE 38393
  • dopaminergic agents would be useful for the treatment of substance abuse and other addictive behavior disorders, including cocaine addiction, nicotine addiction and eating disorders.
  • Affective disorders the most common psychiatric disorders in adults, which are characterized by changes in mood as the primary clinical manifestation, result from a reduction in the central nervous system of certain biogenic amine neurotransmitters, such as dopamine, noradrenaline and serotonin.
  • biogenic amine neurotransmitters such as dopamine, noradrenaline and serotonin.
  • antidepressants work primarily by raising biogenic amine neurotransmitter levels, by either inhibiting their uptake or preventing their metabolism. No antidepressant drug to date, however, can substitute for electroconvulsive shack therapy for the treatment of severe, suicidal depression.
  • ADHD Attention Deficit Hyperactivity Disorder
  • dopamine has been identified with a number of effects in the periphery, and has been used in the treatment of shock, congestive heart failure and acute renal failure. Stimulation of the peripheral D-1 receptors causes vasodilation, particularly in the renal arid mesenteric vascular beds where large numbers of these receptors are found.
  • the utility of dopamine has been limited, however, by its ability to cause vasoconstriction at higher concentrations, presumably due to its secondary effects on adrenergic receptors, and by its emetic effects due to peripheral D-2 stimulation.
  • Agents selective for the peripheral D-1 receptors appear to offer significant advantages over currently used treatments for these and other related disorders.
  • dopamine in combination with diuretics has been reported to reverse radio-contrast media-induced acute renal failure in patients (Talley at al., Clin. Res., 18:518, 1970); thus suggesting that dopamine agonists may be similarly useful.
  • a wide variety of structures has been disclosed that are dopamine receptor ligands (H.E. Katerinopoulos and D.I. Schuster, "Structure- Activity
  • Nichols at al. have disclosed certain substituted trans- hexahydrobenzo[a]-phenanthridine compounds as dopaminergic ligands (United States Patent 5,047,536, to D. E. Nichols, issued 1991; W.K. Brewster al., "trans-1 0,1 l-dihydroxy-5,6,6a,7,8,l 2b-hexahydrobenzo[a]phenanthridine: A Highly Potent Selective Dopamine Dl Full Agonist", in Journal of Medicinal Chemistry, D:1756- 1784, 1990).
  • the present invention is directed to monoester and asymmetrically substituted diester derivatives of such compounds and their receptor agonist substituted derivatives and analogs, where either one of the hydroxy groups is acylated with an ester-forming group or each of the adjacent phenolic hydroxy groups is acylated with a different ester-forming group.
  • the compounds of the present invention exhibit unexpectedly improved pharmacokinetic properties, as compared to the previous described unacylated "parent" compounds. DETAILED DESCRIPTION OF THE INVENTION
  • the present invention is directed to mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine Dl agonists of Formulas I, II and III above and their optionally substituted derivatives wherein one of Ri and R 2 is hydrogen or acetyl and the other one is selected from the group consisting of (C 3 -C 0 ) alkanoyl; halo- (C 3 -C 20 ) alkanoyl; (C 3- C 20 ) alkenoyl; (C 4 -C 7 ) cycloalkanoyl; (C 3 -C 6 )- cycloalkyl(C 2 -C 16 ) alkanoyl; aroyl which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (CrC 3 ) alkyl and (CrC 3 ) alkoxy, which latter may in turn
  • a compound for Formula I, II or III above or their optionally substituted derivatives wherein one of Ri and R 2 is hydrogen or acetyl and the other one is selected from the group consisting of (C 3 -C 20 ) alkanoyl, (C 4 -C 7 ) cycloalkanoyl, benzoyl which is unsubstituted or substituted by a chlorine atom or 1 to 3 methoxy groups, phenylacetyl which may be substituted with a chlorine atom, and heteroarylacetyl.
  • a compound of the general Formulas I, II or III above or their substituted derivatives wherein one of R ⁇ and R 2 is hydrogen and the other is selected from the group consisting of propanoyl, propenoyl, butanoyl, isobutanoyl, pivaloyl, decanoyl, hexadecanoyl, cyclopropanoyl and benzoyl.
  • a compound of the Formulas I and II or III or their substituted derivatives wherein one of Ri and R 2 is acetyl and the other is selected from the group consisting of butanoyl, isobutanoyl, cyclopropanoyl, cyclohexanoyl, pivaloyl, decanoyl and hexadecanoyl.
  • halo and halogen are used to designate fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine.
  • (C -C 0 ) alkanoyl is used to designate the residue of a saturated aliphatic carboxylic acid of 3 to 20 carbon atoms, the carbon chain of which may be straight or branched. Examples of such alkanoyl groups are e.g.
  • propanoyl isopropanoyl, butanoyl, 2-mefhylpropanoyl, pentanoyl, 3-methyl-butanoyl, pivaloyl, n-hexanoyl, n-heptanoyl, n-octanoyl, n-nonanoyl, n-decanoyl, palmitoyl, stearoyl and eicosanoyl.
  • halo-(C -C 20 ) alkanoyl is used to designate a (C 3 - C 20 )alkanoyl group as defined above which is substituted by at least one halogen atom, preferably by 1 to 3 halogen atoms.
  • (C 3 -C 20 ) alkenoyl is used to designate the residue of an aliphatic carboxylic acid of 3 to 20 carbon atoms, the carbon chain of which may be straight or branched and which contains 1 to 3 conjugated or non-conjugated double- bonds.
  • alkenoyl groups are, e.g. acryloyl, mefhacryloyl, linoleoyl and linolenoyl.
  • (C 4 -C ) cycloalkanoyl is used to designate a group having the formula
  • n is an integer 1 to 4.
  • Such groups include cyclopropanoyl, cyclobutanoyl, cyclopentanoyl and cyclohexanoyl.
  • the term "(C 3 -C 6 ) cycloalkyl-(C 2 -C ⁇ 6 ) alkanoyl" is used to designate a group having the formula
  • n is defined as above, nl is an integer 1 to 15, and the alkylene chain (C n ⁇ H 2nl ) maybe straight or branched.
  • alkylene chain C n ⁇ H 2nl
  • examples of such groups are, e.g. cyclopropyl acetyl, cyclohexyl acetyl, cyclopropyl hexanoyl and cyclopropyl palmitoyl.
  • aroyl is used to designate, for example, benzoyl, 1- naphthoyl and 2-naphthoyl.
  • Said aroyl group is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (C ⁇ -C 3 )-alkyl and (C ⁇ -C 3 )alkoxy, which alkyl and alkoxy groups in turn may be substituted by 1 to 3 halogen atoms.
  • substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (C ⁇ -C 3 )-alkyl and (C ⁇ -C 3 )alkoxy, which alkyl and alkoxy groups in turn may be substituted by 1 to 3 halogen atoms.
  • substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (C ⁇ -C 3 )-alkyl and (C ⁇ -C 3 )alkoxy, which alkyl and alkoxy groups
  • (C 1 -C 3 )alkyl is used to designate methyl, ethyl, propyl and isopropyl and the term “(C ⁇ -C 3 )alkoxy” is used to designate methoxy, ethoxy, propoxy and isopropoxy.
  • aryl-(C 2 -C ⁇ 6 )alkanoyl is used to designate a group of the formula
  • Aryl and n ⁇ are as previously defined and the alkylene chain (C Intel ⁇ H 2n ⁇ ) may be straight or branched.
  • the aryl moiety of said group may be substituted with substituents as indicated in connection with the aroyl groups above.
  • Examples of aryl- (C 2 -C ⁇ 6 )alkanoyl groups are phenacetyl. p-chlorophenacetyl, p- trifluoromefhoxyphenylacetyl and phenylhexanoyl.
  • hetero-arylalkanoyl groups having one to three heteroatoms selected from O, S and N in the hetero-aryl moiety and 2 to 10 carbon atoms in the alkanoyl moiety and which are unsubstituted or substituted in the heteroaryl moiety as indicated above are thiophen-2-yl-acetyl and pyrid-4-yl-hexanoyl.
  • (C ⁇ -C 4 )alkyl is used to designate a straight or branched alkyl group of 1 to 4 carbon atoms including methyl, ethyl, propyl, isopropyl, butyl, 1 -methyl propyl, 2-methyl propyl and t-butyl.
  • a process for the preparation of a mono-ester derivative of Formula I, II or III and derivatives thereof a) reacting a compound of Formula I, II or III (or a derivative thereof) with an acid chloride of the general formula: wherein R 4 is as defined for said other one of R ⁇ and R 2 above, in the molar ratio of the compound to acid chloride of from 1:1 to 1:5 and in trifluoracetic acid and methylene chloride (CH 2 C1 2 ); b) after the reaction being completed, evaporating the solvents or lyophilizing the reaction mixture; c) dissolving the residual crude product mixture in CH 2 C1 2 and purifying by chromatography on Al 2 O 3 eluting with CH 2 C1 2 and then with t- BuOH:CH 2 Cl 2 or EtOH:CH 2 Cl 2 mixtures in a stepwise gradient of increasing concentration of t-BuOH and EtOH.
  • R 5 -C1 wherein R 5 is as defined for said other one of R ⁇ and R 2 above, in the molar ratio of mono-ester to acid chloride of from 1:1 to 1:5 and trifluoroacetic acid and methylene chloride (CH 2 C1 2 ); b) after the reaction being completed, evaporating the solvents or lyophilizing the reaction mixture; c) dissolving the residual crude product mixture in CH 2 C1 2 and purifying by chromatography on Al 2 O eluting with CH C1 2 and then with t- BuOH:CH 2 Cl 2 or EtOH:CH 2 Cl 2 mixtures in a stepwise gradient of increasing concentration of t-BuOH and EtOH, respectively, of from 1 to 16% by volume, preferably from 2 to 10% by volume, of the mixture, and isolating fractions containing the isomeric di-ester derivatives of the formula (1); and d) optionally, but preferably separating said isomeric di-ester derivatives by known techniques to isolate a single di-
  • a mono-ester of a compound of Formula I, II or III, wherein R ⁇ and R 2 are as defined above except that neither thereof is acetyl is reacted with acetyl chloride in step a) in the molar ratio of mono-ester to acetyl chloride of from 1 :1 to 1 :6 and trifluoroacetic acid and methylene chloride (CH 2 C1 2 ), whereafter steps b) to d) as above follows.
  • a mono-ester wherein Ri and R 2 are as defined above except that neither thereof is acetyl is reacted in step a) with acetic acid anhydride in CH 2 C1 2 in the presence of a basic catalyst such as triethylamine or pyridine whereafter steps b) to d) as above follows.
  • a mono-acetyl ester is reacted with the anhydride of an acid of the formula
  • Catechols are very sensitive to oxidation (e.g. in atmospheric air). This is especially true under basic conditions. It is thus virtually impossible to handle such catechols in the free base form, without the addition of antioxidants.
  • pro-drugs of the present invention are designed to be easily hydrolyzed, making it difficult to use SiO 2 and nucleophilic alcohols for purification of the esters of the invention via column chromatography.
  • step a) of the processes according to the present invention the esterification, for example of dihydrexidine or dinapsoline or its mono-acetyl ester, respectively, is performed under acidic conditions in trifluoroacetic acid (CF 3 COOH) diluted with methylene chloride (CH 2 C1 2 ), a suitable dilution ratio being about 3-10 times.
  • the acid chloride possibly dissolved in CH 2 C1 2 , is added to dihydrexidine or dinapsoline or its mono-acetyl ester, respectively, at a molar ratio between dihydrexidine or dinapsoline or its respective mono-ester to acid chloride of from 1:1 to 1:5.
  • the optimal ratio will vary depending on the steric properties of the acid chloride but will generally be within the range of from 1:1 to 1:2.
  • the reaction can be monitored by means of thin layer chromatography (Al 2 O 3 and eluting with CH 2 C1 2 or CH 2 Cl 2 :t-BuOH mixtures or CH 2 Cl 2 :EtOH mixtures).
  • the solvents are evaporated from the reaction mixture or the reaction mixture is lyophilized in step b) of the processes of the invention. Evaporation of the solvents is generally carried out under reduced pressure.
  • the residual crude product mixture from step b) is, in step c) dissolved in CH 2 C1 2 and purified, for example, by chromatography on Al 2 O 3 , elution being carried out by using first CH 2 C1 2 and then with mixtures of t-BuOH and CH 2 C1 2 in a stepwise gradient of increasing concentration of t-BuOH of from 1 to 15% by volume of t- BuOH calculated on the mixture, preferably from 2 to 10% by volume, for instance in steps of 1.0, 2.0, 5.0 and 10%.
  • elution fractions containing the desired isomeric ester derivatives are collected.
  • the isomeric mono-esters may then be separated using known techniques such as flash chromatography, preparative HPLC (High Performance Liquid Chromatography), crystallization and other methods known per se.
  • known techniques such as flash chromatography, preparative HPLC (High Performance Liquid Chromatography), crystallization and other methods known per se.
  • some of the isomeric mono-esters may prove difficult to separate and in such a case the mixture of the two isomers may be used as the starting material for the preparation of asymmetric di-esters or as the active principle in a pharmaceutical preparation.
  • the asymmetric di-esters In case of the preparation of the asymmetric di-esters, starting from an individual mono-ester isomer, the asymmetric di-esters will typically elute first and unreacted mono-esters thereafter.
  • a pharmaceutical composition comprising, as an active principle, at least one monoester or asymmetric di-ester of a compound of Formulas I, II and III as defined above (including optionally substituted derivatives) or a physiologically acceptable salt thereof together with a pharmaceutically acceptable carrier, diluent or excipient.
  • ester pro-drugs of Formulas I, II and III and their optionally substituted derivatives, according to the invention may be incorporated in the pharmaceutical composition according to the invention as the base or as an acid addition salt, especially the hydrochloride salt.
  • suitable salts are those formed by the acids HBr and sulphonic acids like methanesulphonic acid, octanesulphonic acid and hexadecansulphonic acid.
  • administration refers to systemic use, as when taken orally, parenterally, by inhalation spray, by nasal, rectal or buccal routes, or topically in dosage form unit formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants and vehicles, as desired.
  • parenteral includes intravenous, intramuscular, intraperitoneal. intrastemal, subcutaneous and intraarticular injection and infusion techniques.
  • pharmaceutically-acceptable is meant those salts and esters, which are within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio, effective for their intended use in the treatment of psychological, neurological, cardiovascular and addictive behavior disorders.
  • pharmaceutically-acceptable carriers means a inert solid, semi-solid or liquid filler, diluent, encapsulating material or r ⁇ ulation auxiliary of any type.
  • sugars such as lactose, glucose and sucrose: starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogenfree water; isotonic saline; Ringers solution
  • wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
  • antioxidants examples include water- soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like; oil soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol and the like; and the metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like.
  • water- soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like
  • oil soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lec
  • a “therapeutically-effective amount” of a dopaminergic agent is meant a sufficient amount of the compound to treat dopamine-related disorders at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically-effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender and diet of the patient: the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidentally with the specific compound employed; and like factors well known in the medical arts.
  • cognate disorder refers to disorders that are characterized by changes in mood as the primary clinical manifestation, for example, depression.
  • anti psychotic agent refers to drugs used extensively in the symptomatic management of all forms of schizophrenia, organic psychosis, the manic phase of manic depressive illness and other acute idiopathic illnesses and occasionally used in depression or in severe anxiety.
  • the term "attention deficit disorder” refers to a recently-classified pediatric neuropsychiatric disorder characterized by inattention, impulsivity, distractibility and sometimes hyperactivity, which replaces the less formal diagnoses of hyperactivity syndrome, hyperkinetic syndrome, minimal brain dysfunction and specific learning disability.
  • the disorder is prevalent among pre-adolescent children and is reflected in poor school performance and social behavior and has been described in experimental reports of impaired perceptual, cognitive and motor function.
  • cognitive impairment refers to a deficiency in any of the aspects of the is cognitive (information processing) functions of perceiving, thinking and remembering.
  • dopamine-related cardiovascular disorders refers to conditions which can be reversed or improved by administration of dopamine or a dopaminergic agent, either alone or in combination therapy with other classes of cardiovascular agents.
  • the usefulness of dopaminergic agents in cardiovascular diseases is based on the known, but incompletely understood, role of dopamine in the cardiovascular system, especially the effects of dopamine on the heart and the ability of dopamine to produce vasoconstriction while maintaining blood flow through renal and mesenteric beds.
  • other related, potential uses for dopaminergic agents which include, for example, use in renal failure.
  • dopamine-related neurological and psychological disorders refers to behavioral disorders, such as psychoses and addictive behavior disorders; affective disorders, such as major depression; and movement disorders, such as Parkinson's Disease, Huntington's Disease and Gilles de la Tourette's syndrome; which have been linked, pharmacologically and/or clinically, to either insufficient or excessive functional dopaminergic activity In the CNS.
  • miscellaneous indications for which dopaminergic agents have been found to be clinically useful include disorders characterized by vomiting, such as uremia, gastroenteritis, carcinomatosis, radiation sickness, and emesis caused by a variety of drugs; intractable hiccough and alcoholic hallucinosis.
  • Normal dopamine levels are those levels of dopamine that are found in the brains of control subjects and are usually measured as levels of the dopamine metabolites homovanillic acid (3-methoxy-4-hydroxphenylacetic acid) and 3,4- dihydroxyphenylacetic acid.
  • Abnormal dopamine levels are those levels that are not within the range of dopamine levels found in the brains of control subjects.
  • substance abuse is used herein to mean periodic or regular self-administration of psychoactive substances in the absence of medical indications and despite the presence of persistent or recurrent social, occupational, psychological or physical problems that the person knows are caused by or may be exacerbated by continued use of the substance.
  • the total daily dose of the compounds of this invention administered to a host in single or in divided doses may be in amounts, for example, from 0.01 to 50 mg/kg body weight or more, usually from 0.1 to 30 mg/kg body weight
  • Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
  • treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in multiple doses or in a single dose.
  • the compounds of the present invention may be administered alone or in combination or in concurrent therapy with other agents which affect the dopaminergic system, for example, L-dopa, amantadine, apomorphine or bromocryptine; and with cholinergic agents, for example, benztropine, biperiden, ethopromazine, procyclidine, trihexylphenidyl, and the like.
  • agents for example, enzyme inhibitors, which block their metabolic transformation outside the CNS.
  • compositions in unit dosage forms comprising a therapeutically-effective amount of a compound (or compounds) of this invention in combination with a conventional pharmaceutical carrier.
  • injectable preparations for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3- butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringers solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed, including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid, are used in the preparation of injectables.
  • the injectable formulation may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which may be dissolved or dispersed in sterile water or other sterile injectable medium lust prior to use.
  • sterilizing agents in the form of sterile solid compositions which may be dissolved or dispersed in sterile water or other sterile injectable medium lust prior to use.
  • the most common way to accomplish this is to inject a suspension of the drug in a crystalline or amorphous material which has poor water solubility
  • the rate of absorption of the drug becomes dependent on the rate of dissolution of the drug which is, in turn, dependent on the physical state of the drug, for example, the crystal size of the drug and its crystalline form.
  • Injectable depot forms may also be made by forming microcapsule matrices of drugs and biodegradable polymers, such as with polylactidle- polyglycolide.
  • the rate of drug release may be controlled by this method.
  • biodegradable polymers include poly-orthoesters and polyanhydrides.
  • the depot injectables can also be made by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • Suppositories for rectal administration of the drug may be prepared by mixing the drug with a suitable non irritating excipient, such as cocoa butter and polyethylene glycol, both of which are solid at ordinary temperature, but liquid at the rectal temperature and will therefore melt in the rectum, releasing the drug.
  • a suitable non irritating excipient such as cocoa butter and polyethylene glycol, both of which are solid at ordinary temperature, but liquid at the rectal temperature and will therefore melt in the rectum, releasing the drug.
  • Solid dosage forms for oral administration may include capsules, tablets, pills, powders, pills and granules.
  • the active compound may be admixed with at least one inert diluent, such as sucrose, lactose or starch.
  • inert diluent such as sucrose, lactose or starch.
  • dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. Tablets and pills may additionally be prepared with enteric coatings and other release-controlling coatings.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like.
  • Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water, such compositions may also comprise adjuvants, such as welling agents: emulsifying and suspending agents; sweetening, flavoring and perfuming agents.
  • the compounds of the present invention can be incorporated into slow release or targeted-delivery systems, such as polymer matrices, liposomes and microspheres.
  • the active compounds may also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells, such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents, and may also be of a composition that they release the active ingredient(s) only, or preferably, in a certain part of the intestinal tract, optionally In a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention further include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or transdermal patches.
  • the active component is admixed under sterile conditions with a pharmaceutically-acceptable carrier and any needed preservatives or buffers, as required.
  • Ophthalmic formulations, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • Administration sublingually, from one or more of the above dosage forms, is also contemplated as a suitable mode of administration of the compounds of the invention.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays may contain, in addition to the compounds of this invention, excipients, such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays may additionally contain customary propellants. such as chlorofluorohydrocarbons or environmentally- and pharmaceutically-acceptable substitutes.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
  • dosage forms may be made by dissolving or dispersing the compound in the proper medium.
  • Absorption enhancers may also be used to increase the flux of the compound across the skin.
  • the rate may be controlled by either providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Mono-ester and asymmetrically substituted diesters of dihydrexidine, dinapsoline and A-86929 and substituted derivatives thereof are described. The novel ester/diester derivatives exhibit improved pharmacokinetic characteristics relative to their unesterified parent compounds and can be formulated into pharmaceutical compositions useful for the treatment of a wide variety of dopamine related disorders.

Description

MONO-ESTER AND ASYMMETRICALLY SUBSTITUTED DI-ESTER PRO- DRUGS OF THE DOPAMINE Dl RECEPTOR AGONISTS
FIELD OF THE INVENTION
This invention relates to novel mono-ester and asymmetrically substituted di-ester pro-drugs of dopamine Dl receptor agonists, useful for treating dopamine-related neurological, psychological, cardiovascular, cognitive and behavioral disorders.
BACKGROUND OF THE INVENTION
Dopamine is an important neurotransmitter in the central nervous system (CNS), as where it is involved with motor function, perception, arousal, motivation and emotion. Dopamine imbalance is believed to play a key role in a number of CNS-related disorders such as schizophrenia, Parkinson's disease, drug abuse, eating disorders and depression. Dopamine also has several important roles in the peripheral nervous system, such as in the control of blood to the kidneys and in autotonomic ganglion transmission.
Dopamine receptors in the CNS have traditionally been divided into two general categories, designated D-l and D-2 receptors, based on biochemical and pharmacological differences between the two receptor types, and more recently from the study of the molecular biology of dopamine receptors in the CNS. (For a review of the classification and function of dopamine receptor subtypes, see C. Kaiser and T. Jain, "Dopamine Receptors: Functions, Subtypes and Emerging Concepts", Medicinal Research Reviews, 5:145-229, 1985.) Recent additional evidence has suggested an even greater heterogeneity of the dopamine receptors with three additional dopamine receptors being defined through molecular cloning techniques: the D3 and D4, which are classified as D2-like, and the D5, which exhibits Dl receptor-like pharmacology (D. Sibley and F. Monsma, "Molecular Biology of Dopamine receptors", in TIPS, Vol. 13, pp. 61-69, 1992). Attempts to understand the physiological and pathophysiological roles of the various dopamine receptors are continuing to unveil new avenues for novel therapeutic approaches for the treatment of dopamine-related disorders. A particular dopamine-related problem involves the loss of striatal dopamine within the basal ganglia, the region of the mammalian brain that is involved with motor control, which has been established as the fundamental deficit in Parkinson's Disease and primary to the etiology of that disease state. This deficiency is addressed via dopamine replacement therapy, primarily with L DOPA (3,4-dihydroxyphenylalanine), which is converted to dopamine within the brain. L-DOPA has been the cornerstone of Parkinson's Disease therapy, and the successes achieved with its therapy have led to the testing of other compounds capable of eliciting the post-synaptic receptor actions of dopamine. Bromocriptine, the most widely used direct-acting dopamine agonist for the treatment of Parkinson's Disease, is administered adjunctively with L-DOPA in order to lower dosage of L-DOPA required to achieve the desired therapeutic response. Bromocriptine alone has been shown to relieve Parkinson's Disease symptoms in some patients, allowing for a delay in the onset of L-DOPA therapy, but the response to bromocriptine alone is not as great as that observed with L DOPA. The current therapies for Parkinson's Disease, including L-DOPA and bromocriptine, are, however, unfortunately associated with a number of serious side-effects and limitations, such as the development of dyskinesias, severe response fluctuations (on- off phenomenon) and diminishing efficacy during treatment. An excess of dopamine in the brain, on the other hand, has bean identified, as a result of the pioneering work of Carlsson and others in the 1960's, as the cause of schizophrenia, a psychiatric illness involving disturbance of thought processes, hallucinations and loss of touch with reality. Chronic abuse of stimulants, such as amphetamines, known to enhance dopaminergic activity in the brain, can lead to a paranoid psychosis that is clinically indistinguishable from classic paranoid schizophrenia, further supporting this dopamine theory of schizophrenia.
Anti-schizophrenic drugs are postulated to exert their effects by blocking the dopamine receptors (i.e., acting as receptor antagonists), and consequently preventing excess receptor stimulation (G.P. Reynolds, "Developments in the drug treatment of schizophrenia", in TIPS, :116-121, 1992). These antipsychotic agents frequently produce undesirable side-effects, however, the most common of which are the extrapyramidal effects that include bizarre involuntary movements and Parkinson-like states, as well as sedation and hypotension. Because of these often severe side-effects and the high incidence of patients unresponsive to dopamine blocking drugs, novel and improved therapies continue to be sought.
One such complement to dopamine receptor antagonists has included the use of low doses of dopamine agonists, such as apomorphine and bromocriptine. which have been reported to produce anti psychotic effects, possibly due to preferential activation of dopamine presynaptic receptors resulting in decreased dopaminergic activity (M. Del Zompo et al, "Dopamine agonists in the treatment of schizophrenia", Progress in Brain Research, E:41-48, 1986 end H. Y. Meltzer, "Novel Approaches to the Pharmacology of Schizophrenia", Drug Development Research, 9:23-40, 1986). In addition, the dopamine Dl-selective agonist, SKF 38393, when used in conjunction with the antipsychotic drug, haloperidol, a D2 antagonist, has been shown to ameliorate the undesired side-effects of the haloperidol (M. Davidson, "Effects of the D-1 Agonist SKF-38393 Combined With Haloperidol in Schizophrenic Patients", Arch Gen. Psychiatry, 42 : 190- 191 , 1990).
Growing evidence (reviewed by R.A. Wise and P.P. Rompre in "Brain Dopamine and Reward", Annual Review of Psychology, 40:191-225, 1989) suggests that dopamine also has a central role in the brain's reward system. For example, animals trained to self-administer cocaine will increase their consumption of this drug after treatment with either a D-1 or a D-2 receptor antagonist, presumably in order to maintain the elevated dopamine levels responsible for the drug's euphorigenic and reinforcing properties (D.R. Britten et al, "Evidence for Involvement of Both Dl and D2 Receptors in Maintaining Cocaine Self- Administration", Pharmacology Biochemistry & Behavior, 89:911-915, 1991). The D-1 agonist, SKE 38393, has also been reported to decrease food intake by rats, presumably by direct action of the drug on neural feeding mechanisms. Because of this interrelationship between dopamine and reward, dopaminergic agents would be useful for the treatment of substance abuse and other addictive behavior disorders, including cocaine addiction, nicotine addiction and eating disorders. Affective disorders, the most common psychiatric disorders in adults, which are characterized by changes in mood as the primary clinical manifestation, result from a reduction in the central nervous system of certain biogenic amine neurotransmitters, such as dopamine, noradrenaline and serotonin. Currently available antidepressants work primarily by raising biogenic amine neurotransmitter levels, by either inhibiting their uptake or preventing their metabolism. No antidepressant drug to date, however, can substitute for electroconvulsive shack therapy for the treatment of severe, suicidal depression.
Currently-available drugs for treating affective disorders, unfortunately, suffer from delayed onset of action, poor efficacy, anticholinergic effects at therapeutic doses, cardiotoxicity, convulsions and the possibility of overdosing. A large number of clinically depressed individuals remain refractory to currently- available therapies.
A role for direct-acting dopamine agonists in antidepressant therapy has been suggested based on the effects observed for several dopamine agonists In various animal models (R. Muscat et al., "Antidepressant-like effects of dopamine agonists in an animal model of depression", Biological Psychiatry, 31:937-946, 1992). A role for dopamine has also been established in cognition and attention mechanisms. Animal studies support the role of dopamine in attention- related behaviors involving search and exploratory activity, distractibility, response rate, discriminability and the switching of attention. Treatment of cognitive impairment and attention deficit disorders via dopamine-based therapy has been proposed and is under active investigation (F. Levy, 'The Dopamine Theory of
Attention Deficit Hyperactivity Disorder (ADHD)", in Australian and New Zealand Journal of Psychiatry, 2:277-283, 1991).
In addition, dopamine has been identified with a number of effects in the periphery, and has been used in the treatment of shock, congestive heart failure and acute renal failure. Stimulation of the peripheral D-1 receptors causes vasodilation, particularly in the renal arid mesenteric vascular beds where large numbers of these receptors are found. The utility of dopamine has been limited, however, by its ability to cause vasoconstriction at higher concentrations, presumably due to its secondary effects on adrenergic receptors, and by its emetic effects due to peripheral D-2 stimulation. Agents selective for the peripheral D-1 receptors appear to offer significant advantages over currently used treatments for these and other related disorders. Also, dopamine in combination with diuretics has been reported to reverse radio-contrast media-induced acute renal failure in patients (Talley at al., Clin. Res., 18:518, 1970); thus suggesting that dopamine agonists may be similarly useful. A wide variety of structures has been disclosed that are dopamine receptor ligands (H.E. Katerinopoulos and D.I. Schuster, "Structure- Activity
Relationships for Dopamine Analogs A Review", in Drugs Of The Future, Vol. 12, pp. 223-253, 1987) and include the thienopyridines, SKF 86926 (4-(3',4'- dihydroxyphenyl) 4,5,6,7-tetrahydrotheno (2,3-c)-pyridine) and SKF 86915 (7- (3'.4'dihydroxyphenyl)-4,5,6,7-tetrahydrothlieno (3,2-c)-pyridine) (P.H. Andersen et al„ European Journal of Pharmacology, 137:291-292, 1987, United States Patents 4,340,600, to L. M. Brenner and J.R. Wardell, Jr., issued 1982, and 4,282,227, to L.M. Brenner, issued 1981). Nichols at al. have disclosed certain substituted trans- hexahydrobenzo[a]-phenanthridine compounds as dopaminergic ligands (United States Patent 5,047,536, to D. E. Nichols, issued 1991; W.K. Brewster al., "trans-1 0,1 l-dihydroxy-5,6,6a,7,8,l 2b-hexahydrobenzo[a]phenanthridine: A Highly Potent Selective Dopamine Dl Full Agonist", in Journal of Medicinal Chemistry, D:1756- 1784, 1990).
United States Patents 5,047,536 and 6,194,423, incorporated herein, describe and claim the dopamine Dl agonists dihydrexidine (Formula I) and dinapsoline (Formula II) and their optionally substituted derivatives, respectively. PCT/US94/02894 describes the dopamine D-1 agonist A-86929 (Formula III), its diacylated derivated form (Formula IN) and other optionally substituted derivatives of A-86929. For the purpose of describing and specifying this invention, Formulas I- III shall be representative of dihydrexidine, dinapsoline, A-86929, respectively, and the various Ν- and C- substituted derivatives thereof described in the above-mentioned patent literature.
Figure imgf000007_0001
Dihydrexidine (R! = R2 = H) Dinapsoline (Rj = R2 = H) (I) (II)
Figure imgf000007_0002
A-86929 (R!= R2 = H) ABT431 (R, = R2 = Ac) (III) (IV)
Each of the "parent" compounds (Ri = R2 = H) of Formulas I-III and their D-1 receptor agonist substituted derivatives/analogs share a common structural feature: adjacent phenolic hydroxy groups. The present invention is directed to monoester and asymmetrically substituted diester derivatives of such compounds and their receptor agonist substituted derivatives and analogs, where either one of the hydroxy groups is acylated with an ester-forming group or each of the adjacent phenolic hydroxy groups is acylated with a different ester-forming group. The compounds of the present invention exhibit unexpectedly improved pharmacokinetic properties, as compared to the previous described unacylated "parent" compounds. DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine Dl agonists of Formulas I, II and III above and their optionally substituted derivatives wherein one of Ri and R2 is hydrogen or acetyl and the other one is selected from the group consisting of (C3-C 0) alkanoyl; halo- (C3-C20) alkanoyl; (C3-C20) alkenoyl; (C4-C7) cycloalkanoyl; (C3-C6)- cycloalkyl(C2-C16) alkanoyl; aroyl which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (CrC3) alkyl and (CrC3) alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms; aryl (C2-Cι6) alkanoyl which is unsubstituted or substituted in the aryl moiety by 1 to 3 substituents selected from the group consisting of halogen, (CrC3) alkyl and (Cι-C ) alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms; and hetero-arylalkanoyl having one to three heteroatoms selected from O, S and N in the heteroaryl moiety and 2 to 10 carbon atoms in the alkanoyl moiety and which is unsubstituted or substituted in the heteroaryl moiety by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (Cι-C3) alkyl, and (d-C ) alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms, and the physiologically acceptable salts thereof. According to one embodiment of the present invention there is provided a compound for Formula I, II or III above or their optionally substituted derivatives, wherein one of Ri and R2 is hydrogen or acetyl and the other one is selected from the group consisting of (C3-C20) alkanoyl, (C4-C7) cycloalkanoyl, benzoyl which is unsubstituted or substituted by a chlorine atom or 1 to 3 methoxy groups, phenylacetyl which may be substituted with a chlorine atom, and heteroarylacetyl.
According to another embodiment of the present invention there is provided a compound of the general Formulas I, II or III above or their substituted derivatives, wherein one of R\ and R2 is hydrogen and the other is selected from the group consisting of propanoyl, propenoyl, butanoyl, isobutanoyl, pivaloyl, decanoyl, hexadecanoyl, cyclopropanoyl and benzoyl. According to another embodiment of the present invention there is provided a compound of the Formulas I and II or III or their substituted derivatives, wherein one of Ri and R2 is acetyl and the other is selected from the group consisting of butanoyl, isobutanoyl, cyclopropanoyl, cyclohexanoyl, pivaloyl, decanoyl and hexadecanoyl.
With regard to the
Figure imgf000009_0001
and R2 in Formulas I and II and III above, the following meanings generally apply:
The terms "halo" and "halogen" are used to designate fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine. The term "(C -C 0) alkanoyl" is used to designate the residue of a saturated aliphatic carboxylic acid of 3 to 20 carbon atoms, the carbon chain of which may be straight or branched. Examples of such alkanoyl groups are e.g. propanoyl, isopropanoyl, butanoyl, 2-mefhylpropanoyl, pentanoyl, 3-methyl-butanoyl, pivaloyl, n-hexanoyl, n-heptanoyl, n-octanoyl, n-nonanoyl, n-decanoyl, palmitoyl, stearoyl and eicosanoyl.
The term "halo-(C -C20) alkanoyl" is used to designate a (C3- C20)alkanoyl group as defined above which is substituted by at least one halogen atom, preferably by 1 to 3 halogen atoms.
The term "(C3-C20) alkenoyl" is used to designate the residue of an aliphatic carboxylic acid of 3 to 20 carbon atoms, the carbon chain of which may be straight or branched and which contains 1 to 3 conjugated or non-conjugated double- bonds. Examples of such alkenoyl groups are, e.g. acryloyl, mefhacryloyl, linoleoyl and linolenoyl.
The term "(C4-C ) cycloalkanoyl" is used to designate a group having the formula
Figure imgf000009_0002
wherein n is an integer 1 to 4.
Such groups include cyclopropanoyl, cyclobutanoyl, cyclopentanoyl and cyclohexanoyl. The term "(C3-C6) cycloalkyl-(C2-Cι6) alkanoyl" is used to designate a group having the formula
Figure imgf000010_0001
wherein n is defined as above, nl is an integer 1 to 15, and the alkylene chain (CnιH2nl) maybe straight or branched. Examples of such groups are, e.g. cyclopropyl acetyl, cyclohexyl acetyl, cyclopropyl hexanoyl and cyclopropyl palmitoyl. The term "aroyl" is used to designate, for example, benzoyl, 1- naphthoyl and 2-naphthoyl. Said aroyl group is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (Cι-C3)-alkyl and (Cι-C3)alkoxy, which alkyl and alkoxy groups in turn may be substituted by 1 to 3 halogen atoms. Examples of such substituted aroyl groups are m-methoxybenzoyl, p-trifuoromethoxybenzoyl. p- chlorobenzoyl, 3,4,5-trimethoxybenzoyl, p-cyanobenzoyl and 3-chloro-l-napthoyl.
The term "(C1-C3)alkyl" is used to designate methyl, ethyl, propyl and isopropyl and the term "(Cι-C3)alkoxy" is used to designate methoxy, ethoxy, propoxy and isopropoxy. The term "aryl-(C2-Cι6)alkanoyl" is used to designate a group of the formula
O
Aιyl-(CnιH2n1)-C-
wherein Aryl and n\ are as previously defined and the alkylene chain (C„ιH2nι) may be straight or branched. The aryl moiety of said group may be substituted with substituents as indicated in connection with the aroyl groups above. Examples of aryl- (C2-Cι6)alkanoyl groups are phenacetyl. p-chlorophenacetyl, p- trifluoromefhoxyphenylacetyl and phenylhexanoyl. Examples of hetero-arylalkanoyl groups having one to three heteroatoms selected from O, S and N in the hetero-aryl moiety and 2 to 10 carbon atoms in the alkanoyl moiety and which are unsubstituted or substituted in the heteroaryl moiety as indicated above are thiophen-2-yl-acetyl and pyrid-4-yl-hexanoyl. The term "(Cι-C4)alkyl" is used to designate a straight or branched alkyl group of 1 to 4 carbon atoms including methyl, ethyl, propyl, isopropyl, butyl, 1 -methyl propyl, 2-methyl propyl and t-butyl.
According to another aspect of the invention there are provided methods for the preparation of compounds of Formulas I, II and III above and their optionally substituted derivatives.
Accordingly, in one method embodiment, there is provided a process for the preparation of a mono-ester derivative of Formula I, II or III and derivatives thereof: a) reacting a compound of Formula I, II or III (or a derivative thereof) with an acid chloride of the general formula:
Figure imgf000011_0001
wherein R4 is as defined for said other one of R\ and R2 above, in the molar ratio of the compound to acid chloride of from 1:1 to 1:5 and in trifluoracetic acid and methylene chloride (CH2C12); b) after the reaction being completed, evaporating the solvents or lyophilizing the reaction mixture; c) dissolving the residual crude product mixture in CH2C12 and purifying by chromatography on Al2O3 eluting with CH2C12 and then with t- BuOH:CH2Cl2 or EtOH:CH2Cl2 mixtures in a stepwise gradient of increasing concentration of t-BuOH and EtOH. respectively, of from 1 to 15% by volume, preferably from 2 to 10% by volume, of the mixture, and isolating fractions containing the isomeric mono-ester derivatives and d) optionally but preferably separating said isomeric mono-ester derivative products known techniques.
According to the present invention there is also provided a process for the preparation of di-ester derivatives of compounds of the general Formula I, II and III (or substituted derivatives thereof) wherein one of Ri and R2 is acetyl and the other one is selected from the group consisting of (C3-C20)alkanoyl; halo- (C3-C20)alkanoyl; (C3-C o)alkenoyl: (C4-C7)cycloalkanoyl; (C3-C6)-cycloalkyl(C2-Cι6)alkanoyl; aroyl which is unsubstituted or substituted by 1 to 5 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (Cι-C3)alkyl and (Ci- C )alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms; aryl(C2- Cι6)alkanoyl which is unsubstituted or substituted in the aryl moiety by 1 to 3 substituents selected from the group consisting of halogen, (C1-C3)alkyl and (Ci- C3)alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms; and hetero-arylalkanoyl having one to three heteroatoms selected from O, S and N in the heteroaryl moiety and 2 to 10 carbon atoms in the alkanoyl moiety and which is unsubstituted or substituted in the heteroaryl moiety by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (C\-
C3)alkyl, and (d-C3)alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms; which process comprises a) reacting a mono-ester of one of the compounds of Formula I, II or III, wherein one of R\ and R2 is hydrogen and the other one is acetyl with an acid chloride of the general formula:
R5-C1 wherein R5 is as defined for said other one of R\ and R2 above, in the molar ratio of mono-ester to acid chloride of from 1:1 to 1:5 and trifluoroacetic acid and methylene chloride (CH2C12); b) after the reaction being completed, evaporating the solvents or lyophilizing the reaction mixture; c) dissolving the residual crude product mixture in CH2C12 and purifying by chromatography on Al2O eluting with CH C12 and then with t- BuOH:CH2Cl2 or EtOH:CH2Cl2 mixtures in a stepwise gradient of increasing concentration of t-BuOH and EtOH, respectively, of from 1 to 16% by volume, preferably from 2 to 10% by volume, of the mixture, and isolating fractions containing the isomeric di-ester derivatives of the formula (1); and d) optionally, but preferably separating said isomeric di-ester derivatives by known techniques to isolate a single di-ester.
In a first modification of the method for the preparation of a di-ester derivative, a mono-ester of a compound of Formula I, II or III, wherein R\ and R2 are as defined above except that neither thereof is acetyl, is reacted with acetyl chloride in step a) in the molar ratio of mono-ester to acetyl chloride of from 1 :1 to 1 :6 and trifluoroacetic acid and methylene chloride (CH2C12), whereafter steps b) to d) as above follows. In another modification of the method for the preparation of a di-ester derivative of Formula I, II or III or a substituted derivative thereof, a mono-ester wherein Ri and R2 are as defined above except that neither thereof is acetyl, is reacted in step a) with acetic acid anhydride in CH2C12 in the presence of a basic catalyst such as triethylamine or pyridine whereafter steps b) to d) as above follows. Alternatively, a mono-acetyl ester is reacted with the anhydride of an acid of the formula
R5-OH
wherein R is as defined above, in a step a) in CH2C12 in the presence of a basic s catalyst such as triethylamine or pyridine whereafter steps b) to d) as above follows.
Catechols, are very sensitive to oxidation (e.g. in atmospheric air). This is especially true under basic conditions. It is thus virtually impossible to handle such catechols in the free base form, without the addition of antioxidants.
In addition, the pro-drugs of the present invention are designed to be easily hydrolyzed, making it difficult to use SiO2 and nucleophilic alcohols for purification of the esters of the invention via column chromatography.
In step a) of the processes according to the present invention the esterification, for example of dihydrexidine or dinapsoline or its mono-acetyl ester, respectively, is performed under acidic conditions in trifluoroacetic acid (CF3COOH) diluted with methylene chloride (CH2C12), a suitable dilution ratio being about 3-10 times. The acid chloride, possibly dissolved in CH2C12, is added to dihydrexidine or dinapsoline or its mono-acetyl ester, respectively, at a molar ratio between dihydrexidine or dinapsoline or its respective mono-ester to acid chloride of from 1:1 to 1:5. The optimal ratio will vary depending on the steric properties of the acid chloride but will generally be within the range of from 1:1 to 1:2. The reaction can be monitored by means of thin layer chromatography (Al2O3 and eluting with CH2C12 or CH2Cl2:t-BuOH mixtures or CH2Cl2:EtOH mixtures).
After the reaction has become complete (generally within 1-24 h, depending on the acid chloride and molar ratio used) the solvents are evaporated from the reaction mixture or the reaction mixture is lyophilized in step b) of the processes of the invention. Evaporation of the solvents is generally carried out under reduced pressure.
For purification according to step c) of the processes of the present invention the residual crude product mixture from step b) is, in step c) dissolved in CH2C12 and purified, for example, by chromatography on Al2O3, elution being carried out by using first CH2C12 and then with mixtures of t-BuOH and CH2C12 in a stepwise gradient of increasing concentration of t-BuOH of from 1 to 15% by volume of t- BuOH calculated on the mixture, preferably from 2 to 10% by volume, for instance in steps of 1.0, 2.0, 5.0 and 10%. During the elution fractions containing the desired isomeric ester derivatives are collected.
The isomeric mono-esters may then be separated using known techniques such as flash chromatography, preparative HPLC (High Performance Liquid Chromatography), crystallization and other methods known per se. However, some of the isomeric mono-esters may prove difficult to separate and in such a case the mixture of the two isomers may be used as the starting material for the preparation of asymmetric di-esters or as the active principle in a pharmaceutical preparation.
In case of the preparation of the asymmetric di-esters, starting from an individual mono-ester isomer, the asymmetric di-esters will typically elute first and unreacted mono-esters thereafter.
Also in this case, when starting from a mixture of the two possible isomers of the mono-ester resulting from the esterification process of the present invention, the two di-ester isomers may prove difficult to separate and so it may appear advantageous to use the mixture of isomers as the active principle in a pharmaceutical preparation rather than taking the cost for the separation of the isomers. According to a further aspect of the present invention there is provided a pharmaceutical composition comprising, as an active principle, at least one monoester or asymmetric di-ester of a compound of Formulas I, II and III as defined above (including optionally substituted derivatives) or a physiologically acceptable salt thereof together with a pharmaceutically acceptable carrier, diluent or excipient. The term "at least one" as used in the paragraph next above is primarily meant to refer to the case when the mixture of two isomers resulting from the esterification process of the present invention is difficult to separate and hence it might appear advantageous to use said mixture rather than a single isomer. It might also appear advantageous to use the mixture of the two isomers or a combination of two compounds according to the invention having different combinations of the meanings of the symbols Ri and R2 in Formulas I, II and III between each other. The ester pro-drugs of Formulas I, II and III and their optionally substituted derivatives, according to the invention may be incorporated in the pharmaceutical composition according to the invention as the base or as an acid addition salt, especially the hydrochloride salt. Other suitable salts are those formed by the acids HBr and sulphonic acids like methanesulphonic acid, octanesulphonic acid and hexadecansulphonic acid.
The term "administration" of the dopaminergic agent or composition, as used herein, refers to systemic use, as when taken orally, parenterally, by inhalation spray, by nasal, rectal or buccal routes, or topically in dosage form unit formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants and vehicles, as desired.
The term "parenteral" as used herein includes intravenous, intramuscular, intraperitoneal. intrastemal, subcutaneous and intraarticular injection and infusion techniques.
By "pharmaceutically-acceptable" is meant those salts and esters, which are within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio, effective for their intended use in the treatment of psychological, neurological, cardiovascular and addictive behavior disorders. As used herein, the term "pharmaceutically-acceptable carriers" means a
Figure imgf000016_0001
inert solid, semi-solid or liquid filler, diluent, encapsulating material or rϊulation auxiliary of any type. Some examples of the materials that can serve as pharmaceutically-acceptable carriers are sugars, such as lactose, glucose and sucrose: starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogenfree water; isotonic saline; Ringers solution; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. Examples of pharmaceutically-acceptable antioxidants include water- soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like; oil soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol and the like; and the metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like. By a "therapeutically-effective amount" of a dopaminergic agent is meant a sufficient amount of the compound to treat dopamine-related disorders at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically-effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender and diet of the patient: the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidentally with the specific compound employed; and like factors well known in the medical arts.
The term "affective disorder" as used herein refers to disorders that are characterized by changes in mood as the primary clinical manifestation, for example, depression.
The term "anti psychotic agent' as used herein refers to drugs used extensively in the symptomatic management of all forms of schizophrenia, organic psychosis, the manic phase of manic depressive illness and other acute idiopathic illnesses and occasionally used in depression or in severe anxiety.
The term "attention deficit disorder" refers to a recently-classified pediatric neuropsychiatric disorder characterized by inattention, impulsivity, distractibility and sometimes hyperactivity, which replaces the less formal diagnoses of hyperactivity syndrome, hyperkinetic syndrome, minimal brain dysfunction and specific learning disability. The disorder is prevalent among pre-adolescent children and is reflected in poor school performance and social behavior and has been described in experimental reports of impaired perceptual, cognitive and motor function.
The term "cognitive impairment" refers to a deficiency in any of the aspects of the is cognitive (information processing) functions of perceiving, thinking and remembering.
The term "dopamine-related cardiovascular disorders" as used herein refers to conditions which can be reversed or improved by administration of dopamine or a dopaminergic agent, either alone or in combination therapy with other classes of cardiovascular agents. The usefulness of dopaminergic agents in cardiovascular diseases, for example in the treatment of shock and congestive heart failure, is based on the known, but incompletely understood, role of dopamine in the cardiovascular system, especially the effects of dopamine on the heart and the ability of dopamine to produce vasoconstriction while maintaining blood flow through renal and mesenteric beds. Also included are other related, potential uses for dopaminergic agents which include, for example, use in renal failure.
The term "dopamine-related neurological and psychological disorders" as used herein refers to behavioral disorders, such as psychoses and addictive behavior disorders; affective disorders, such as major depression; and movement disorders, such as Parkinson's Disease, Huntington's Disease and Gilles de la Tourette's syndrome; which have been linked, pharmacologically and/or clinically, to either insufficient or excessive functional dopaminergic activity In the CNS. Also included are miscellaneous indications for which dopaminergic agents have been found to be clinically useful. Examples of such indications include disorders characterized by vomiting, such as uremia, gastroenteritis, carcinomatosis, radiation sickness, and emesis caused by a variety of drugs; intractable hiccough and alcoholic hallucinosis.
"Normal dopamine levels" are those levels of dopamine that are found in the brains of control subjects and are usually measured as levels of the dopamine metabolites homovanillic acid (3-methoxy-4-hydroxphenylacetic acid) and 3,4- dihydroxyphenylacetic acid. Abnormal dopamine levels are those levels that are not within the range of dopamine levels found in the brains of control subjects.
The term "substance abuse" is used herein to mean periodic or regular self-administration of psychoactive substances in the absence of medical indications and despite the presence of persistent or recurrent social, occupational, psychological or physical problems that the person knows are caused by or may be exacerbated by continued use of the substance.
The total daily dose of the compounds of this invention administered to a host in single or in divided doses may be in amounts, for example, from 0.01 to 50 mg/kg body weight or more, usually from 0.1 to 30 mg/kg body weight Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in multiple doses or in a single dose. The compounds of the present invention may be administered alone or in combination or in concurrent therapy with other agents which affect the dopaminergic system, for example, L-dopa, amantadine, apomorphine or bromocryptine; and with cholinergic agents, for example, benztropine, biperiden, ethopromazine, procyclidine, trihexylphenidyl, and the like. The compounds of the present invention may also be co-administered with agents, for example, enzyme inhibitors, which block their metabolic transformation outside the CNS.
This invention also provides pharmaceutical compositions in unit dosage forms, comprising a therapeutically-effective amount of a compound (or compounds) of this invention in combination with a conventional pharmaceutical carrier. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3- butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringers solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides. Also, fatty acids, such as oleic acid, are used in the preparation of injectables.
The injectable formulation may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which may be dissolved or dispersed in sterile water or other sterile injectable medium lust prior to use. In order to prolong the effect of a drug, it is often desirable to slow the absorption of a drug from subcutaneous or intramuscular injection. The most common way to accomplish this is to inject a suspension of the drug in a crystalline or amorphous material which has poor water solubility The rate of absorption of the drug becomes dependent on the rate of dissolution of the drug which is, in turn, dependent on the physical state of the drug, for example, the crystal size of the drug and its crystalline form. Another approach to delaying absorption of a drug is to administer the drug as a solution or suspension in oil. Injectable depot forms may also be made by forming microcapsule matrices of drugs and biodegradable polymers, such as with polylactidle- polyglycolide.
Depending on the ratio of drug to polymer and the composition of the polymer, the rate of drug release may be controlled by this method. Examples of other biodegradable polymers include poly-orthoesters and polyanhydrides. The depot injectables can also be made by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
Suppositories for rectal administration of the drug may be prepared by mixing the drug with a suitable non irritating excipient, such as cocoa butter and polyethylene glycol, both of which are solid at ordinary temperature, but liquid at the rectal temperature and will therefore melt in the rectum, releasing the drug.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders, pills and granules. In such solid dosage forms the active compound may be admixed with at least one inert diluent, such as sucrose, lactose or starch., such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose.
In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills may additionally be prepared with enteric coatings and other release-controlling coatings.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like. Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water, such compositions may also comprise adjuvants, such as welling agents: emulsifying and suspending agents; sweetening, flavoring and perfuming agents. If desired, the compounds of the present invention can be incorporated into slow release or targeted-delivery systems, such as polymer matrices, liposomes and microspheres. The active compounds may also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells, such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents, and may also be of a composition that they release the active ingredient(s) only, or preferably, in a certain part of the intestinal tract, optionally In a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
Dosage forms for topical or transdermal administration of a compound of this invention further include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or transdermal patches. The active component is admixed under sterile conditions with a pharmaceutically-acceptable carrier and any needed preservatives or buffers, as required. Ophthalmic formulations, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention. Administration sublingually, from one or more of the above dosage forms, is also contemplated as a suitable mode of administration of the compounds of the invention.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays may contain, in addition to the compounds of this invention, excipients, such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants. such as chlorofluorohydrocarbons or environmentally- and pharmaceutically-acceptable substitutes.
Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms may be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers may also be used to increase the flux of the compound across the skin. The rate may be controlled by either providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.

Claims

Claims
1. The present invention is directed to mono-ester and asymmetrically substituted di-ester pro-drugs of dopamine Dl agonists of the following formulas:
Figure imgf000022_0001
(I) (II)
Figure imgf000022_0002
(III)
wherein one of R\ and R2 is hydrogen or acetyl and the other one is selected from the group consisting of (C3-C20)alkanoyl; halo- (C3-C 0)alkanoyl; (C -C20)alkenoyl: (C4- C )cycloalkanoyl; (C3-C6)-cycloalkyl(C2-C16)alkanoyl; aroyl which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonylox)4 (Cι-C3)alkyl and (Cι-C3)alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms; aryl(C2-C16)alkanoyl which is unsubstituted or substituted in the aryl moiety by 1 to 3 substituents selected from the group consisting of halogen, (Cι-C )alkyl and (Cι-C )alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms: and hetero-arylalkanoyl having one to three heteroatoms selected from O, S and N in the heteroaryl moiety and 2 to 10 carbon atoms in the alkanoyl moiety and which is unsubstituted or substituted in the heteroaryl moiety by 1 to 3 substituents selected from the group consisting of halogen, cyano, trifluoromethanesulphonyloxy, (d-C3)alkyl, and (d-C3)alkoxy, which latter may in turn be substituted by 1 to 3 halogen atoms, and the physiologically acceptable salts thereof.
2. A compound of Formula I, wherein R\ is H or acetyl and R2 is pivaloyl.
3. A compound of Formula I, wherein R2 is H or acetyl and Ri is pivaloyl.
4. A compound of Formula II, wherein Ri is H or acetyl and R2 is pivaloyl.
5. A compound of Formula III, wherein R2 is H or acetyl and Ri is pivaloyl.
6. A compound of Formula III, wherein Ri is H or acetyl and R2 is pivaloyl.
7. A compound of Formula III, wherein R2 is H or acetyl and Ri is pivaloyl,
8. A pharmaceutical composition for selectively binding and activating dopaminergic receptors comprising a pharmaceutically-acceptable carrier and a therapeutically-effective amount of a compound according to claim 1.
9. A pharmaceutical composition for treating dopamine-related neurological, psychological, cardiovascular, cognitive or attention disorders or substance abuse or addictive behavior, or a combination of these indications, comprising a pharmaceutically-acceptable carrier and a therapeutically-effective amount of a compound of claim 1.
10. A method for treating dopamine-related neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse or addictive behavior, or a combination of these indications, characterized by abnormal dopaminergic activity comprising administering to a patient in need of such treatment a therapeutically-acceptable amount of a compound according to claim 1.
11. The use of a compound of claim 1 in the manufacture of a medicament for treating dopamine-related disorders.
PCT/US2003/004592 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists WO2003070245A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2003569201A JP2005526728A (en) 2002-02-15 2003-02-14 Monoester and asymmetrically substituted diester prodrugs of dopamine D1 receptor agonists
CA002476115A CA2476115A1 (en) 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
AU2003217430A AU2003217430B2 (en) 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted Di-ester pro-drugs of the dopamine D1 receptor agonists
DK03713475T DK1480647T3 (en) 2002-02-15 2003-02-14 Monoester or asymmetrically substituted diester ester prodrugs of dopamine D1 receptor agonists
US10/503,796 US7220754B2 (en) 2002-02-15 2003-02-14 Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide D1 receptor agonists
EP03713475A EP1480647B1 (en) 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
DE60323339T DE60323339D1 (en) 2002-02-15 2003-02-14 MONOESTER AND ASYMMETRICALLY SUBSTITUTED DIESTER PRODRUGS OF DOPAMINE D1 RECEPTOR AGONISTS
NO20043634A NO20043634L (en) 2002-02-15 2004-08-31 Mono-ester and asymmetrically substituted di-ester prodrugs of dopamine D1 receptor agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0200478A SE0200478D0 (en) 2002-02-15 2002-02-15 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonist A-86929
SE0200478-6 2002-02-15
SE0200474-5 2002-02-17
SE0200474A SE0200474D0 (en) 2002-02-17 2002-02-17 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonists Dihydrexidine and Dinapsoline

Publications (2)

Publication Number Publication Date
WO2003070245A1 true WO2003070245A1 (en) 2003-08-28
WO2003070245B1 WO2003070245B1 (en) 2004-05-27

Family

ID=27759833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004592 WO2003070245A1 (en) 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists

Country Status (11)

Country Link
US (1) US7220754B2 (en)
EP (1) EP1480647B1 (en)
JP (1) JP2005526728A (en)
AT (1) ATE406896T1 (en)
AU (1) AU2003217430B2 (en)
CA (1) CA2476115A1 (en)
DE (1) DE60323339D1 (en)
DK (1) DK1480647T3 (en)
ES (1) ES2314189T3 (en)
NO (1) NO20043634L (en)
WO (1) WO2003070245A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699450A2 (en) * 2003-12-23 2006-09-13 Darpharma, INC. Co-administration of dopamine-receptor binding compounds

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8596306B2 (en) * 2005-10-27 2013-12-03 Synthetic Gas Solutions, Llc Perfluorocarbon gas insufflation
EP2010541A2 (en) * 2006-02-21 2009-01-07 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
EP2421862B1 (en) 2009-04-21 2014-06-11 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
US20150291625A1 (en) * 2012-11-08 2015-10-15 Pfizer Inc. Heteroaromatic Compounds and their Use as Dopamine D1 Ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
US6194423B1 (en) * 1995-08-18 2001-02-27 Purdue Research Foundation Fused isoquinolines as dopamine receptor ligands

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
US4282227A (en) * 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
JPH02138A (en) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd L-dopa derivative
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
KR100292928B1 (en) * 1992-05-26 2001-11-05 프란시스 제이 메이어 Substituted hexahydrobenzophenanthridine
ATE233765T1 (en) * 1993-04-06 2003-03-15 Abbott Lab TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS
JPH10502923A (en) * 1994-07-15 1998-03-17 パーデュー・リサーチ・ファンデーション Optically active isomers of dihydrexidine and its substituted analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
US6194423B1 (en) * 1995-08-18 2001-02-27 Purdue Research Foundation Fused isoquinolines as dopamine receptor ligands

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699450A2 (en) * 2003-12-23 2006-09-13 Darpharma, INC. Co-administration of dopamine-receptor binding compounds
EP1699450A4 (en) * 2003-12-23 2009-11-11 Darpharma Inc Co-administration of dopamine-receptor binding compounds

Also Published As

Publication number Publication date
DK1480647T3 (en) 2009-01-26
ES2314189T3 (en) 2009-03-16
JP2005526728A (en) 2005-09-08
NO20043634L (en) 2004-11-11
ATE406896T1 (en) 2008-09-15
WO2003070245B1 (en) 2004-05-27
US7220754B2 (en) 2007-05-22
US20050096469A1 (en) 2005-05-05
AU2003217430B2 (en) 2008-10-23
EP1480647B1 (en) 2008-09-03
EP1480647A4 (en) 2005-07-13
CA2476115A1 (en) 2003-08-28
DE60323339D1 (en) 2008-10-16
EP1480647A1 (en) 2004-12-01
AU2003217430A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
TWI330640B (en) Pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds therefor
RU2167152C2 (en) N-substituted azaheterocyclic carboxylic acids or their pharmaceutically acceptable salts, method of their synthesis, pharmaceutical composition based on thereof and method of inhibition of neurogenic inflammation
JP3346562B2 (en) PCP receptor / ligand and drugs containing them
DE69432217T2 (en) TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS
US20190231734A1 (en) Doxepin Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders
EP1480647B1 (en) Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
DE69628360T2 (en) Azepinon compounds for use in inhibiting ACE and NEP
ITMI951900A1 (en) REPLACED HYDROISOKINOLINIC DERIVATIVES
DE69905798T2 (en) Di- or triazaspiro [4,5] decane derivatives
US5668141A (en) Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phenanthrene compounds as dopamine agonists
US4923863A (en) Morpholine derivatives, pharmaceutical compositions and use
CN108610292A (en) Bis- substituted glycolylurea class compounds of a kind of 3,5- and the preparation method and application thereof
US6046200A (en) Compositions having neuroprotective and analgesic activity
US5114945A (en) Spiropiperidine derivatives
KR0168508B1 (en) Anxiolytic agent
CA2643300C (en) Trans-fused chromenoisoquinolines, synthesis and methods for use
EP0003286B1 (en) Derivatives of ergopeptide alkaloids, process for their preparation and pharmaceutical compositions containing them
US5955493A (en) Thiamorphinans with neuroprotective activity
KR20090010133A (en) Serotonin transport inhibitors
TW202321258A (en) Oxaspiro derivative, and preparation method therefor and use thereof
CA2159481C (en) Tetracyclic compounds as dopamine agonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
B Later publication of amended claims

Effective date: 20030522

WWE Wipo information: entry into national phase

Ref document number: 10503796

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003713475

Country of ref document: EP

Ref document number: 2476115

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003569201

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003217430

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2003713475

Country of ref document: EP